Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection

1 Apr 2021

Abstract excerpt

BACKGROUND: Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept challenge study that evaluated safety, immunogenicity, and efficacy of the Flexyn2a vaccine to protect...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Escherichia coli research studies
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33862589
DOI: 10.1016/j.ebiom.2021.103310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protectionPMID 33862589Read ↗

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I StudySemantic proximity Read ↗

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult SubjectsSemantic proximity Read ↗

Towards establishing a correlate of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei 1790GAHB GMMA investigational vaccineSemantic proximity Read ↗

Status of vaccine research and development for ShigellaSemantic proximity Read ↗

Towards establishing correlates of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) candidate vaccine (1790GAHB).Semantic proximity Read ↗

A next-generation GMMA-based vaccine candidate to fight shigellosisSemantic proximity Read ↗

The Shigella Vaccines PipelineSemantic proximity Read ↗

Frontiers in Shigella Vaccine DevelopmentSemantic proximity Read ↗

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity scoreSemantic proximity Read ↗

From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine’s Refinement and EvolutionSemantic proximity Read ↗

Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to ShigellaSemantic proximity Read ↗

Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE ConferenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.